Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
From enrollment during pregnancy up to 1 year after delivery for infant follow-up (maximum approximatively 20 months)
Age
18–55
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Women with Multiple Sclerosis who were or became pregnant within the period of time between the first infusion of a course of treatment with LEMTRADA to 4 months after their last infusion for that course.
Women able and willing to provide informed consent for study participation and the requirement of the study. Informed consent will be obtained at the time of enrollment in accordance with local regulatory requirements.
You may not be if
\- Previous enrollment in this study for a previous pregnancy.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | LEMTRADA Pregnancy Registry in Multiple Sclerosis
